What is BostonGene?
BostonGene is at the forefront of the transition to personalized medicine, leveraging its proprietary AI-based molecular and immune profiling platform. The company's BostonGene Tumor PortraitTM Tests provide a comprehensive analysis of each tumor, detailing immune microenvironment properties, actionable mutations, biomarkers for therapy response, and recommended treatment strategies. This detailed diagnostic approach generates a personalized roadmap for oncologists, enabling more precise therapeutic decision-making for cancer patients and aiming to improve treatment outcomes and economic efficiencies within healthcare.
How much funding has BostonGene raised?
BostonGene has raised a total of $200M across 2 funding rounds:
Series A
$50M
Series B
$150M
Series A (2019): $50M, investors not publicly disclosed
Series B (2022): $150M led by Japan Industrial Partners, NEC Corporation, and Impact Investment Capital
Key Investors in BostonGene
Japan Industrial Partners
Japan Industrial Partners is an investment fund focused on revitalizing businesses in Japan, providing capital and management support for corporate restructuring and carve-outs. They partner with large enterprises to enhance operations and foster growth.
NEC Corporation
NEC Corporation is a multinational information technology and electronics company. Their involvement suggests a strategic interest in BostonGene's AI and healthcare technology applications.
Impact Investment Capital
Impact Investment Capital is an investment entity focused on funding companies with significant societal or environmental impact. Their participation highlights BostonGene's mission-driven approach to healthcare innovation.
What's next for BostonGene?
With the recent infusion of major strategic capital, BostonGene is poised for significant expansion and further development of its AI-driven diagnostic capabilities. The company's focus on personalized medicine, particularly through its advanced tumor profiling, positions it to capitalize on the growing demand for precision oncology solutions. Future growth is likely to involve scaling its commercial operations, forging strategic partnerships within the healthcare and pharmaceutical sectors, and continuing to innovate its analytical platform to address complex oncological challenges and further integrate into clinical decision-making workflows.
See full BostonGene company page
